Atria Investments LLC invests $1.37 million in PerkinElmer, Inc. (NYSE: PKI)


Atria Investments LLC bought a new position in PerkinElmer, Inc. (NYSE: PKI – Get Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 7,841 shares of the medical research company, valued at around $1,368,000.

Other hedge funds and other institutional investors also bought and sold shares of the company. DekaBank Deutsche Girozentrale increased its position in PerkinElmer shares by 1.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 12,797 shares of the medical research company valued at $2,294,000 after buying an additional 192 shares last quarter. Fifth Third Bancorp increased its stake in PerkinElmer shares by 81.3% during the fourth quarter. Fifth Third Bancorp now owns 1,916 shares of the medical research company valued at $385,000 after acquiring 859 additional shares in the last quarter. Principal Financial Group Inc. increased its holdings of PerkinElmer shares by 6.4% during the fourth quarter. Principal Financial Group Inc. now owns 173,521 shares of the medical research company valued at $34,888,000 after buying an additional 10,465 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in PerkinElmer by 26.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 23,472 shares of the medical research company worth $4,720,000 after buying 4,841 additional shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in PerkinElmer by 2.2% in the fourth quarter. Mackenzie Financial Corp now owns 25,780 shares of the medical research company worth $5,183,000 after acquiring an additional 550 shares during the period. Institutional investors hold 89.27% ​​of the company’s shares.

PerkinElmer stock up 1.0%

NYSE PKI shares opened at $147.86 on Wednesday. PerkinElmer, Inc. has a 1-year low of $130.65 and a 1-year high of $203.16. The company has a debt ratio of 0.68, a current ratio of 1.94 and a quick ratio of 1.43. The company has a 50-day simple moving average of $143.50 and a 200-day simple moving average of $160.41. The company has a market capitalization of $18.65 billion, a P/E ratio of 24.20, a P/E/G ratio of 0.43 and a beta of 1.13.

PerkinElmer (NYSE:PKI – Get Rating) last reported quarterly results on Tuesday, May 3. The medical research company reported earnings per share of $2.41 for the quarter, beating consensus analyst estimates of $2.08 by $0.33. The company posted revenue of $1.26 billion in the quarter, versus $1.19 billion expected by analysts. PerkinElmer had a net margin of 14.54% and a return on equity of 18.98%. PerkinElmer’s quarterly revenue fell 3.7% from the same quarter last year. In the same period a year earlier, the company earned earnings per share of $3.72. On average, stock research analysts expect PerkinElmer, Inc. to post 7.3 earnings per share for the current year.

PerkinElmer announces dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 11. Investors of record on Friday, October 21 will receive a dividend of $0.07 per share. This represents an annualized dividend of $0.28 and a dividend yield of 0.19%. The ex-dividend date is Thursday, October 20. PerkinElmer’s payout ratio is 4.58%.

Changes to analyst ratings

Several brokerages have recently commented on PKI. Goldman Sachs Group lowered its price target on PerkinElmer shares from $200.00 to $175.00 and set a “neutral” rating on the stock in a Thursday, July 14 research report. StockNews.com began covering PerkinElmer in a report on Thursday, March 31. They set a “holding” rating for the company. Barclays launched coverage on PerkinElmer in a research report on Tuesday May 17. They set an “underweight” rating and a price target of $125.00 for the stock. UBS Group launched coverage on PerkinElmer in a research report on Wednesday, July 20. They issued a “buy” rating and a target price of $160.00 on the stock. Finally, Citigroup reduced its target price on PerkinElmer from $185.00 to $170.00 in a Wednesday, May 4 research report. One analyst gave the stock a sell rating, two gave the company a hold rating and five gave the company a buy rating. Based on MarketBeat data, PerkinElmer currently has an average rating of “Moderate Buy” and an average target price of $156.73.

Insider buying and selling

Separately, insider James M. Mock sold 5,025 shares of the company in a trade dated Friday, June 24. The shares were sold at an average price of $145.49, for a total value of $731,087.25. Following the transaction, the insider now directly owns 27,577 shares of the company, valued at approximately $4,012,177.73. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other PerkinElmer news, insider James M. Mock sold 5,025 shares of the company in a trade dated Friday, June 24. The shares were sold at an average price of $145.49, for a total value of $731,087.25. Following the completion of the transaction, the insider now directly owns 27,577 shares of the company, valued at $4,012,177.73. The sale was disclosed in a filing with the SEC, accessible via this link. Additionally, insider Daniel R. Tereau sold 5,700 shares of the company in a trade dated Friday, July 22. The stock was sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the transaction, the insider now owns 13,380 shares of the company, valued at $1,941,973.20. The disclosure of this sale can be found here. 0.52% of the shares are currently held by insiders of the company.

About PerkinElmer

(Get an assessment)

PerkinElmer, Inc provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, computational and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life science research market, as well as contract research and laboratory services.

Read more

Want to see which other hedge funds hold PKIs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for PerkinElmer, Inc. (NYSE:PKI – Get Rating).

Institutional ownership by quarter for PerkinElmer (NYSE: PKI)



Get news and reviews for PerkinElmer Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for PerkinElmer and related companies with MarketBeat.com’s FREE daily email newsletter.